美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Inotek Pharmaceuticals Corporation

3.04

0.0000

成交量：- -

成交额：- -

市值：8,211.04万

市盈率：-1.99

高：3.04

开：3.04

低：3.04

收：3.04

52周最高：3.80

52周最低：0.8500

股本：2,701.00万

流通股本：1,206.00万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.5300

净资产收益率：--

总资产收益率：--

市净率：1.43

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Inotek Pharmaceuticals Corporation

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.inotekpharma.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Inotek制药公司是于1999年7月7日根据美国特拉华州法律成立。该公司是一家临床阶段的生物制药公司，专注于治疗青光眼药物的发现，开发和商业化。该公司领先的候选产品，trabodenoson，是一级可选择的腺苷模拟，腺苷模拟是该公司通过恢复眼睛的自然压力控制机制来降低眼压机制。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ITEK/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ITEK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","market":"US","secType":"STK","nameCN":"Inotek Pharmaceuticals Corporation","latestPrice":3.04,"timestamp":1515099600000,"preClose":3.04,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12060000,"shares":27010000,"eps":-1.53,"marketStatus":"退市","change":0,"latestTime":"01-04 16:00:00 EST","open":3.04,"high":3.04,"low":3.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.53,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","floatShares":12060000,"roa":"--","roe":"--","lyrEps":0,"shares":27010000,"dividePrice":0,"high":3.04,"amplitude":0,"preClose":3.04,"low":3.04,"week52Low":0.85,"pbRate":"1.43","week52High":3.8,"institutionHeld":0,"latestPrice":3.04,"eps":-1.53,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.53,"open":3.04},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ITEK\",params:#limit:5,,,undefined,":[{"date":"2018-01-05","symbol":"ITEK","newSymbol":"RCKT","type":"symbolChange","dateTimestamp":1515128400000},{"market":"US","date":"2017-12-27","symbol":"ITEK","name":"Inotek Pharmaceuticals Corporation","time":"","type":"earning","dateTimestamp":1514350800000,"reportTimeType":""},{"market":"US","date":"2017-08-03","symbol":"ITEK","fiscalQuarterEnding":"2017/06","expectedEps":-0.54,"name":null,"time":"","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"","actualEps":-0.24},{"market":"US","date":"2017-05-10","symbol":"ITEK","fiscalQuarterEnding":"2017/03","expectedEps":-0.35,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-0.4},{"market":"US","date":"2017-03-16","symbol":"ITEK","fiscalQuarterEnding":"2016/12","expectedEps":-0.39,"name":null,"time":"","type":"earning","dateTimestamp":1489636800000,"reportTimeType":"","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ITEK\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inotekpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Inotek制药公司是于1999年7月7日根据美国特拉华州法律成立。该公司是一家临床阶段的生物制药公司，专注于治疗青光眼药物的发现，开发和商业化。该公司领先的候选产品，trabodenoson，是一级可选择的腺苷模拟，腺苷模拟是该公司通过恢复眼睛的自然压力控制机制来降低眼压机制。","exchange":"NASDAQ","name":"Inotek Pharmaceuticals Corporation","nameEN":"Inotek Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":null}}